Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Not applicable Interventional Accepts healthy volunteers

Flushes and Sertraline Trial

NCT00283192
Conditions
Menopause-Hot Flashes
Interventions
Sertraline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
San Francisco, California
Conditions
Menopause, Hot Flashes
Interventions
PhytoSERM, Placebo
Dietary Supplement · Drug
Lead sponsor
NeuTherapeutics
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Terminated No phase listed Observational Accepts healthy volunteers

Validation of an Objective Instrument to Measure Hot Flashes During Menopause

NCT03642119
Conditions
Menopause, Hot Flashes
Interventions
iButton®
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Not listed Phase 4 Interventional Accepts healthy volunteers

Herbal Alternatives for Menopause Symptoms (HALT Study)

NCT00169299
Conditions
Vasomotor Symptoms Associated With Menopause
Interventions
Black cohosh, Multibotanical preparation, Multibotanical preparation + dietary soy counseling, Conjugated equine estrogen +/- medroxyprogesterone acetate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol oral tablet, Placebo oral tablet
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more
Completed Not applicable Interventional Results available

Vilazodone for Menopausal Hot Flashes

NCT01680900
Conditions
Hot Flushes
Interventions
vilazodone, placebo capsules
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers

Mindfulness Based Stress Reduction for Hot Flashes

NCT00317304
Conditions
Hot Flashes, Stress
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
142
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 108 more
Not listed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial Assessing Safety of MF101 for Hot Flushes

NCT01300078
Conditions
Hot Flashes
Interventions
MF101
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
4
States / cities
Berkeley, California • Lincoln, California • Sacramento, California + 1 more
Conditions
Hot Flashes
Interventions
Cenestin 0.3 mg Tablets, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Huntsville, Alabama • Montgomery, Alabama • Phoenix, Arizona + 40 more
Conditions
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Hot Flashes
Interventions
EMBr Wave, Questionnaire Administration
Device · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Nuvigil on Fatigue

NCT01460628
Conditions
Menopause
Interventions
Armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Menopause, Prediabetes, Obesity
Interventions
Placebo, conjugated estrogens/bazedoxifene (CE/BZA)
Other · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions
Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Paxil Use in Menopausal Women

NCT00225914
Conditions
Menopause
Interventions
Paroxetine, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Menopause Related Conditions
Interventions
Sleepwear with Lateralized Thermal Characteristics, Sham-Lateralized Sleepwear
Device
Lead sponsor
St. Peter's Hospital, Albany, NY
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albany, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hot Flashes on Sleep and Mood Disturbance

NCT01116401
Conditions
Menopause, Depression, Hot Flashes
Interventions
leuprolide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of a Kappa Agonist on Hot Flashes in Menopausal Women

NCT02070718
Conditions
Treatment of Menopausal Hot Flashes
Interventions
Standard Dose Kappa Agonist, Half Dose Kappa Agonist, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Seattle, Washington
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Cepham Supplement on Hot Flashes and Menopausal Symptoms in Postmenopausal Women

NCT06939868
Conditions
D008593
Interventions
Shatavari Root Extract, oral capsule
Dietary Supplement
Lead sponsor
Jacksonville University
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Menopause Hot Flashes
Interventions
Placebo, Fezolinetant
Drug
Lead sponsor
Rebecca Thurston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Chicago, Illinois • Pittsburgh, Pennsylvania
Conditions
Hot Flashes, Menopause, Vasomotor Disturbance
Interventions
Low-dose 17-ß-estradiol with progesterone taper, Venlafaxine XR, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
339 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Boston, Massachusetts • Chestnut Hill, Massachusetts • Philadelphia, Pennsylvania + 1 more